$\require{mediawiki-texvc}$
  • 검색어에 아래의 연산자를 사용하시면 더 정확한 검색결과를 얻을 수 있습니다.
  • 검색연산자
검색연산자 기능 검색시 예
() 우선순위가 가장 높은 연산자 예1) (나노 (기계 | machine))
공백 두 개의 검색어(식)을 모두 포함하고 있는 문서 검색 예1) (나노 기계)
예2) 나노 장영실
| 두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색 예1) (줄기세포 | 면역)
예2) 줄기세포 | 장영실
! NOT 이후에 있는 검색어가 포함된 문서는 제외 예1) (황금 !백금)
예2) !image
* 검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색 예) semi*
"" 따옴표 내의 구문과 완전히 일치하는 문서만 검색 예) "Transform and Quantization"

과학기술 지식인프라 ScienceON

상세검색 다국어 입력
도움말도움말
쳇봇 이모티콘
안녕하세요!
ScienceON 챗봇입니다.
궁금한 것은 저에게 물어봐주세요.

논문 상세정보

MyON담기
내보내기

Strategies Against Human Papillomavirus Infection and Cervical Cancer

The journal of microbiology v.42 no.4 , 2004년, pp.255 - 266  
Jung Woon-Won (MyGene Bioscience Institute, Sungok Bldg ) ;  Chun Taehoon ( Department of Microbiology and Immunology, School of Medicine, Hanyang University ) ;  Sul Donggeun ( Environmental Toxico-Genomic and Proteomic Center, College of Medicine, Korea University ) ;  Hwang Kwang Woo ( Department of Immunology, College of Pharmacy, Chung-Ang University ) ;  Kang Hyung-Sik ( School of Biological Sciences and Technology, Biotechnology Research Institute, Chonnam University ) ;  Lee Duck Joo ( Department of Family Medicine, Samsung Cheil Hospital, Sungkyunkwan University ) ;  Han In-Kwon ( MyGene Bioscience Institute, Sungok Bldg, Department of Internal Medicine, Samsung Cheil Hospital, Sungkyunkwan University)
Abstract

Papillomaviruses infect a wide variety of animals, including humans. The human papillomavirus (HPV), in particular, is one of the most common causes of sexually transmitted disease. More than 200 types of HPV have been identified by DNA sequence data, and 85 HPV genotypes have been well char­acterized to date. HPV can infect the basal epithelial cells of the skin or inner tissue linings, and are, accordingly, categorized as either cutaneous or mucosal type. HPV is associated with a panoply of clin­ical conditions, ranging from innocuous lesions to cervical cancer. In the early 1980s, studies first reported a link between cervical cancer and genital HPV infection. Genital HPV infections are now rec­ognized to be a major risk factor in at least $95\%$ of cervical cancers. 30 different HPV genotypes have been identified as causative of sexually transmitted diseases, most of which induce lesions in the cervix, vagina, vulva, penis, and anus, as the result of sexual contact. There is also direct evidence demon­strating that at least four of these genotypes are prerequisite factors in cervical cancer. The main aim of this review was to evaluate the current literature regarding the pathovirology, diagnostics, vaccines, therapy, risk groups, and further therapeutic directions for HPV infections. In addition, we reviewed the current status of HPV infections in South Korean women, as evidenced by our data.

주제어

#cervical cancer   #human papillomavirus   #risk group   #therapy   #vaccine  

참고문헌 (64)

  1. Apple, R.J., T.M. Becker, C.M. Wheeler, and H.A. Erlich. 1995. Comparison of human leukocyte antigen DR-DQ disease associations found with cervical dysplasia and invasive cervical carcinoma. J. Natl. Cancer Inst. 87, 427-436 
  2. Baker, T.S., W.W. Newcomb, N.H. Olson, L.M. Cowsert, C. Olson, and J.C. Brown. 1991. Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and threedimensional image reconstruction. Biophys. J. 60, 1445-1456 
  3. Bontkes, H.J., M. Van Duin, T.D. deGruijl, M.F. Duggan-Keen, J.M. Walboomers, M.J. Stukart, R.H. Vereheijen, T.J. Helmerhorst, C.J. Meijer, R.J. Scheper, F.R. Stevens, P.A. Dyer, P. Sinnott, and P.L. Stern. 1998. HPV 16 infection and progression of cervical intraepithelial neoplasia: analysis of HLA polymorphism and HPV 16 E6 sequences variants. Int. J. Cancer 78, 166-171 
  4. Bontkes, H.J., T.D. deGruijl, J.M. Walboomers, J.T. Schiller, J. Dillner, T.J. Helmerhorst, R.H. Vereheijen, R.J. Scheper, and C.J. Meijer. 1999. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. J. Gen. Virol. 80, 409-417 
  5. Dupuy, C., D. Buzoni-Gatel, A. Touze, D. Bout, and P. Coursaget. 1999. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J. Virol. 73, 9063-9071 
  6. Emeny, R.T., C.M. Wheeler, K.U. Jansen, W.C. Hunt, T.M. Fu, J.F. Smith, S. MacMullen, M.T. Esser, and X. Paliard. 2002. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a viruslike particle vaccine. J. Virol. 76, 7832-7842 
  7. Greenstone, H.L., J.D. Nieland, K.E. de Visser, M.L. De Bruijn, R. Kirnbauer, R.B. Roden, D.R. Lowy, W.M. Kast, and J.T. Schiller. 1998. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl. Acad. Sci. USA 95, 1800- 1805 
  8. Hummel, M., J.B. Hudson, and L.A. Laimins. 1992. Differentiation-induced and constitutive transcription of human papillomavirus type 31b in cell lines containing viral episomes. J. Virol. 66, 6070-6080 
  9. Jeon, S., B.L. Allen-Hoffman, and P.F. Lambert. 1995. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J. Virol. 69, 2989-2997 
  10. Jin, X.W., J. Cash, and A.W. Kennedy. 1999. Human papillomavirus typing and the reduction of cervical cancer risk. Cleveland Clin. J. Med. 66, 533-539 
  11. Kim, K.Y., L. Blatt, and M.W. Taylor. 2000. The effects of interferon on the expression of human papillomavirus oncogenes. J. Gen. Virol. 81, 695-700 
  12. Solomon, D., D. Davey, R. Kurman, A. Moriarity, D. Oconnor, M. Prey, S. Raab, M. Sherman, D. Wilbur, T. Wright, and N. Young. 2002. The 2001 Bethesda System. Terminology for reporting results of cervical cytology. JAMA 287, 2114-2119 
  13. Syrjänen, K.J. 1996. Natural history of genital human papillomavirus infections, p.189-206. In C. Lacey (ed.), Papillomavirus reviews. Leeds University Press, Leeds, United Kingdom 
  14. Villa, L.L. 1997. Human papillomaviruses and cervical cancer. Adv. Cancer Res.71, 321-341 
  15. zur Hausen, H. 1999. Papillomaviruses in human cancers. Proc. Assoc. Am. Physicians 111, 581-587 
  16. Bonnez, W. and R.C. Richman. 1994. Papillomaviruses, p. 1630-1640. In G.L. Mandell, J.E. Bennett, and R. Dolin R (eds.), Nandell, Douglas, and Bennetts principles and practice of infectious diseases, 5th ed. Churchill Livingston, Philadelphia, Pennsylvania 
  17. Muller, M., J. Zhou, T.D. Reed, C. Rittmuller, A. Burger, J. Gabelsberger, J. Braspenning, and L. Gissmann. 1997. Chimeric papillomavirus- like particles. Virology 234, 93-111 
  18. Santin, A.D., P.L. Hermonat, A. Ravaggi, M. Chiriva-Internati, D. Zhan, S. Pecorelli, G.P. Parham, and M.J. Cannon. 1999. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J. Virol. 73, 5402-5410 
  19. Favre, M. 1975. Structural polypeptides of rabbit, bovine, and human papillomaviruses. J. Virol. 15, 1239-1247 
  20. Murray, P.R., K.S. Rosenthal, G.S. Kobayashi, and M.A. Pfaller. 2002. Papovaviruses, p. 460. In Medical Microbiology. Mosby Press, London, United Kingdom 
  21. Okamoto, A., C.D. Woodworth, K. Yen, J. Chun, S. Isonishi, T. Nikaido, T. Kiyokawa, H. Seo, Y. Kitahara, K. Ochiai, and T. Tanaka. 1999. Combination therapy with podophyllin and vidarabine for human papillomavirus positive cervical intraepithelial neoplasia. Oncol. Rep. 6, 269-276 
  22. Orth, G. and Favre, M. 1985. Human papillomaviruses. Biochemical and biologic properties. Clin. Dermatol. 3, 27-42 
  23. Roden, R.B., D.R. Lowy, and J.T. Schiller. 1997. Papillomavirus is resistant to dessication. J. Infect Dis. 176, 1076-1079 
  24. Galloway, D.A. 2003. Papillomavirus vaccines in clinical trials. Lancet Infect. Dis. 3, 469-475 
  25. Adam, E., Z. Berkova, Z. Daxnerova, J. Icenogle, W.C. Reeves, and R.H. Kaufman. 2001. Papillomavirus detection: demographic and behavioral characteristics influencing the identification of cervical disease. Am. J. Obstet. Gynecol. 182, 257-264 
  26. Suzich, J.A., S.J. Ghim, F.J. Palmer-Hill, W.I. White, J.K. Tamura, J.A. Bell, J.A. Newsome, A.B. Jenson, and R. Schlegel. 1995. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. USA 92, 11553-11557 
  27. Ho, G.Y., R. Bierman, L. Beardsley, C.J. Chang, and Burk RD. 1998. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 338, 413-428 
  28. Jacobs, M.V., P.J. Snijders, A.J. van den Brule, T.J. Helmerhorst, C.J. Meijer, and J.M. Walboomers. 1997. A general primermediated PCR enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J. Clin. Microbiol. 35, 791-795 
  29. Magnusson, P.K.E., P. Lichtenstein, and U.B. Gyllenstein. 2000. Heritability of cervical tumors. Int. J. Cancer 88, 698-701 
  30. Evander, M., I.H. Frazer, E. Payne, Y.M. Qui, K. Hengst, and N.A. McMillan. 1997. Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. J. Virol. 71, 2449-2456 
  31. Franco, E.L. 1995. Cancer causes revisited:human papillomavirus and cervical neoplasia. J. Natl. Cancer Inst. 87, 779-780 
  32. Moscicki, A.B., J. Palefsky, G. Smith, S. Siboshski, and G. Schoolnik. 1993. Variability of human papillomavirus DNA testing in a longitudinal cohort of young women. Obstst. Gynecol. 82, 578-585 
  33. Allen, M., M. Kalantari, A. Ylitalo, B. Pettersson, B. Hagmar, L. Scheibenplug, B. Johansson, U. Petterson, and U. Gyllensten. 1996. HLA DQ-DR haplotype and susceptibility to cervical carcinoma: indications of increased risk for development of cervical carcinoma in individuals infected with HPV 18. Tissue Antigens 48, 32-37 
  34. Cubie, H.A., A.L. Seagar, G.J. Beattie, S. Monaghan, and A.R.W. Williams. 2000. A longitudinal study if HPV detection and cervical pathology in HIV infected women. Sex Transm. Infect. 76, 257-261 
  35. Holowaty, P., A.B. Miller, and T.T. Rohan. 1999. Natural dysplasia of the uterine cervix. J. Natl. Cancer Inst. 91, 252-258 
  36. Kleter, B., L.J. van Doorn, L. Schrauwen, A. Molijn, S. Sastrowijoto, J. TerSchegget, J. Lindeman, B. Ter Harmsel, M. Burger, and W. Quint. 1999. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J. Clin. Microbiol. 37, 2508-2517 
  37. Walboomers, J.M.M., M.V. Jacobs, M.M. Manos, F.X. Bosch, J.A. Kummer, K.V. Shah, P.J.F. Snijders, J. Peto, C.J.L. Meijer, and N. Munoz. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12-19 
  38. Burk, R.D., P. Kelly, J. Feldman, J. Bromberg, S.H. Vermund, J.A. Deltovitz, and S.H. Landesman. 1996. Declining presence of cervicovaginal human papilllomavirus infection with age is independent of other risk factors. Sex Transm. Dis. 23, 333-341 
  39. Quint, W.G.V., G. Scholte, L.J. Van Doorn, B. Kleeter, P.H.M. Smits, and J. Lindeman. 2001. Comparative analysis of human papillomavirus infections in cervical scrapes and biopsy specimens by general SPF10 PCR and HPV genotyping. J. Pathol. 194, 51-58 
  40. Harro, C.D., Y.-Y.S. Pang, R.B.S. Roden, A. Hildesheim, Z. Wang, J.M. Reynolds, T.C. Mast, R. Robinson, B.R. Murphy, R.A. Karron, J. Dillner, J.T. Schiller, and D.R. Lowy. 2001. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 93, 284-292 
  41. Koutsky, L.A., K.A. Ault, C.M. Wheeler, D.R. Brown, E. Barr, F.B. Alvarez, L.M. Chiacchierini, and K.U. Jansen. 2002. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1645-1651 
  42. Joyce, J.G., J.-S. Tung, C.T. Przysiecki, J.C. Cook, E.D. Lehman, J.A. Sands, K.U. Jansen, and P.M. Keller. 1999. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J. Biol. Chem. 274 5810-5822. 
  43. Meyers, C., M.G. Frattini, J.B. Hudson, and L.A. Laimins. 1992. Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science 257, 971-973 
  44. Kiviat, N.B. and L.A. Koutsky. 1993. Specific human papillomavirus types as the causal agents of most cervical intraepithelial neoplasia: implications for current views and treatment. J. Natl. Cancer Inst. 85, 934-935 
  45. Lizard, G., M.-J. De´mares-Poulet, P. Roignot, and P. Gambert. 2001. In situ hybridization detection of single-copy human papillomavirus on isolated cells using a catalyzed signal amplification system:GenPoint™. Diagn. Cytopathol. 24, 112-116 
  46. Tomas, M., D. Pim, and L. Banks. 1999. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 18, 7690-7700 
  47. Liu, W.J., K.N. Zhao, F.G. Gao, G.R. Leggatt, G.J. Fernando, and I.H. Frazer. 2001. Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine 20, 862-869 
  48. Christensen, N.D., J.W. Kreider, N.M. Cladel, and D.A. Galloway. 1990. Immunological cross-reactivity to laboratory-produced HPV-11 virions of polysera raised against bacterially derived fusion proteins and synthetic peptides of HPV-6b and HPV-16 capsid proteins. Virology 175, 1-9 
  49. Chua, K.L. and A. Hjerpe. 1996. Persistence of human papillomavirus (HPV) infections preceding cervical carcinoma. Cancer 77, 121-127 
  50. Yang, X., G. Jin, Y. Nakao, M. Rahimtula, M. Pater, and A. Pater. 1996. Malignant transformation of HPV-16 immortalized human endocervical cells by cigarette smoke condensate and characterization of multistage carcinogenesis. Int. J. Cancer 65, 338-344 
  51. Andrei, G., R. Snoeck, J. Piette, P. Delvenne, and E. DeClercq. 1998. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncol. Res. 10, 523-531 
  52. Breitburd F., R. Kirnbauer, N.L. Hubbert, B. Nonnenmacher, C. Trin-Dinh-Desmarquet, G. Orth, J.T. Schiller, and D.R. Lowy. 1995. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 69, 3959-3963 
  53. Calore, E.E., S.M.M. Pereira, and M.J. Cavaliere. 2001. Progression of cervical lesions in HIV-seropositive women: a cytological study. Diagn. Cytopathol. 24, 117-119 
  54. Da Silva D.M., G.L. Eiben, S.C. Fausch, M.T. Wakabayashi, M.P. Rudolf, M.P. Velders, and W.M. Kast. 2001. Cervical cancer vaccines: emerging concepts and developments. J. Cell Physiol. 186, 169-182 
  55. Hines, J.F., S.J. Ghim, N.D. Christensen, J.W. Kreider, W.A. Barnes, R. Schlegel, and A.B. Jenson. 1994. Role of conformational epitopes expressed by human papillomavirus major capsid proteins in the serologic detection of infection and prophylactic vaccination. Gynecol. Oncol. 55, 13-20 
  56. Philips, D.H., and M. NiShé. 1993. Smoking-related DNA adducts in human cervical biopsies. IARC Sci. Publ. 124, 327-330 
  57. Bosch F., M.M. Manos, N. Munoz, M. Sherman, A.M. Jansen, J. Peto, M.H. Shiffman, V. Moreno, R. Kurman, and K.V. Shah. 1995. Prevalence of human HPV in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst. 87, 796-802 
  58. Campo, M.S., G.J. Grindlay, B.W. O'Neil, L.M. Chandrachud, G.M. McGarvie, and W.F. Jarrett. 1993. Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J. Gen. Virol. 74, 945-953. 
  59. Evans, T.G., W. Bonnez, R.C. Rose, S. Koenig, L. Demeter, J.A. Suzich, D. O'Brien, M. Campbell, W.I. White, J. Balsley, and R.C. Reichman. 2001. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J. Infect. Dis. 183, 1485-1493 
  60. Roden, R.B., W.H. Yutzy, R. Fallon, S. Inglis, D.R. Lowy, and J.T. Schiller. 2000. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270, 254-257 
  61. Giroglu, T., L. Florin, F. Schäfer, R.E. Stre, and M. Sapp. 2001. Human papillomavirus infection requires cell surface heparin sulfate. J. Virol. 75, 1565-1570 
  62. Papanicolaou, G.N. 1949. A survey of actualities and potentialities of exfoliative cytology in cancer diagnosis. Ann. Intern. Med. 31, 661-674 
  63. Torrisi, A., A. Del Mistro, G.L. Onnis, F. Merlin, R. Bertorelle, D. Minucci and D. Colposcopy. 2000. Cytology and HPV testing in HIV-positive and HIV-negative women. Eur. J. Gynecol. Oncol. 21, 168-172 
  64. Burd, E.M. 2003. Human papillomavirus and cervical cancer. Clin. Microbiol. Rev. 16, 1-17 

이 논문을 인용한 문헌 (2)

  1. Min, Sang-Kee ; Kim, Sung-Soon ; Choi, Byeong-Sun ; Cho, Kyung-Soon ; Lee, Joo-Yun ; Kim, Seong-Joon ; Bin, Jae-Hun ; Park, Ho-Kuk 2009. "Prevalence of HPV Infection and HPV Genotype Spectrum among Sexually High-Risk Women in Busan" 생명과학회지 = Journal of life science, 19(2): 234~240 
  2. 2014. "" Asian Pacific journal of cancer prevention : APJCP, 15(4): 1521~1525 

원문보기

원문 PDF 다운로드

  • ScienceON :

원문 URL 링크

원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다. (원문복사서비스 안내 바로 가기)

상세조회 0건 원문조회 0건

이 논문과 연관된 기능

DOI 인용 스타일